BioMaxima (BMX) Stock Overview
Produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BMX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BioMaxima S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł11.75 |
| 52 Week High | zł15.65 |
| 52 Week Low | zł10.70 |
| Beta | 0.26 |
| 1 Month Change | -9.27% |
| 3 Month Change | 2.17% |
| 1 Year Change | -9.62% |
| 3 Year Change | -58.33% |
| 5 Year Change | -70.48% |
| Change since IPO | 48.73% |
Recent News & Updates
BioMaxima S.A.'s (WSE:BMX) Price Is Right But Growth Is Lacking
Dec 03
Here's What To Make Of BioMaxima's (WSE:BMX) Decelerating Rates Of Return
Jul 01Recent updates
BioMaxima S.A.'s (WSE:BMX) Price Is Right But Growth Is Lacking
Dec 03Here's What To Make Of BioMaxima's (WSE:BMX) Decelerating Rates Of Return
Jul 01BioMaxima S.A.'s (WSE:BMX) Share Price Boosted 37% But Its Business Prospects Need A Lift Too
Feb 05BioMaxima (WSE:BMX) Is Carrying A Fair Bit Of Debt
Dec 07BioMaxima (WSE:BMX) Is Carrying A Fair Bit Of Debt
Aug 22BioMaxima S.A.'s (WSE:BMX) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Jun 08BioMaxima S.A.'s (WSE:BMX) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Apr 21Returns On Capital Are Showing Encouraging Signs At BioMaxima (WSE:BMX)
Sep 07BioMaxima (WSE:BMX) Seems To Use Debt Quite Sensibly
Mar 07We Think BioMaxima (WSE:BMX) Might Have The DNA Of A Multi-Bagger
Feb 02BioMaxima (WSE:BMX) Knows How To Allocate Capital Effectively
Sep 06We Think BioMaxima (WSE:BMX) Can Stay On Top Of Its Debt
Jun 04Does BioMaxima (WSE:BMX) Have A Healthy Balance Sheet?
Feb 18Are BioMaxima's (WSE:BMX) Statutory Earnings A Good Guide To Its Underlying Profitability?
Jan 14
Shareholder Returns
| BMX | PL Medical Equipment | PL Market | |
|---|---|---|---|
| 7D | -3.3% | -4.0% | -4.8% |
| 1Y | -9.6% | 2.9% | 22.0% |
Return vs Industry: BMX underperformed the Polish Medical Equipment industry which returned 2.9% over the past year.
Return vs Market: BMX underperformed the Polish Market which returned 22% over the past year.
Price Volatility
| BMX volatility | |
|---|---|
| BMX Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in PL Market | 10.9% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: BMX has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: BMX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 135 | Lukasz Urban | www.biomaxima.com |
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibiotics, agaroses and molecular biology media, media and buffers for in vitro cultures, phenotypic micromatrices, plastics and small equipment, basic substrate components, and form.
BioMaxima S.A. Fundamentals Summary
| BMX fundamental statistics | |
|---|---|
| Market cap | zł49.27m |
| Earnings (TTM) | zł649.00k |
| Revenue (TTM) | zł59.11m |
Is BMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMX income statement (TTM) | |
|---|---|
| Revenue | zł59.11m |
| Cost of Revenue | zł31.16m |
| Gross Profit | zł27.95m |
| Other Expenses | zł27.31m |
| Earnings | zł649.00k |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 47.29% |
| Net Profit Margin | 1.10% |
| Debt/Equity Ratio | 30.8% |
How did BMX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 00:34 |
| End of Day Share Price | 2026/03/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioMaxima S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.